{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:00:06Z","timestamp":1780606806502,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11534-w","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:03:55Z","timestamp":1760601835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Enhanced immunogenicity in mouse by recombinant BCG prime and protein boost based on latency antigen Rv1733c and\/or reactivation antigen RpfE"],"prefix":"10.1186","volume":"25","author":[{"given":"Mitra","family":"Ashayeripanah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narcis","family":"Saubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Joseph-Munne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereshteh","family":"Eftekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"issue":"10","key":"11534_CR1","doi-asserted-by":"publisher","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","volume":"13","author":"RM Houben","year":"2016","unstructured":"Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152.","journal-title":"PLoS Med"},{"issue":"10","key":"11534_CR2","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1016\/S1473-3099(20)30728-3","volume":"21","author":"KD Dale","year":"2021","unstructured":"Dale KD, Karmakar M, Snow KJ, Menzies D, Trauer JM, Denholm JT. Quantifying the rates of late reactivation tuberculosis: a systematic review. Lancet Infect Dis. 2021;21(10):e303\u201317.","journal-title":"Lancet Infect Dis"},{"key":"11534_CR3","unstructured":"Global tuberculosis report 2024. Geneva: World Health Organization; 2024. Licence: CC\u00a0BY-NC-SA\u00a03.0\u00a0IGO.\u00a0https:\/\/iris.who.int\/bitstream\/handle\/10665\/379339\/9789240101531-eng.pdf?sequence=1."},{"issue":"24","key":"11534_CR4","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1016\/j.vaccine.2018.03.009","volume":"36","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. BCG vaccine: WHO position paper, February 2018 - recommendations. Vaccine. 2018;36(24):3408\u201310.","journal-title":"Vaccine"},{"issue":"37","key":"11534_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta17370","volume":"17","author":"I Abubakar","year":"2013","unstructured":"Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne JA, Fine PE, Smith PG, Lipman M, Elliman D, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis. Health Technol Assess. 2013;17(37):1\u2013372, v\u2212vi.","journal-title":"Health Technol Assess"},{"issue":"4","key":"11534_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/cid\/cit790","volume":"58","author":"P Mangtani","year":"2014","unstructured":"Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, Rodrigues LC, Smith PG, Lipman M, Whiting PF, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58(4):470\u201380.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"11534_CR7","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(18)30421-3","volume":"18","author":"LK Schrager","year":"2018","unstructured":"Schrager LK, Chandrasekaran P, Fritzell BH, Hatherill M, Lambert PH, McShane H, Tornieporth N, Vekemans J. WHO preferred product characteristics for new vaccines against tuberculosis. Lancet Infect Dis. 2018;18(8):828\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"11534_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1714021","volume":"379","author":"E Nemes","year":"2018","unstructured":"Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, et al. Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med. 2018;379(2):138\u201349.","journal-title":"N Engl J Med"},{"issue":"1","key":"11534_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.tim.2006.11.008","volume":"15","author":"P Andersen","year":"2007","unstructured":"Andersen P. Vaccine strategies against latent tuberculosis infection. Trends Microbiol. 2007;15(1):7\u201313.","journal-title":"Trends Microbiol"},{"issue":"7","key":"11534_CR10","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1128\/IAI.01999-06","volume":"75","author":"MY Lin","year":"2007","unstructured":"Lin MY, Geluk A, Smith SG, Stewart AL, Friggen AH, Franken KL, Verduyn MJ, van Meijgaarden KE, Voskuil MI, Dockrell HM, et al. Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination. Infect Immun. 2007;75(7):3523\u201330.","journal-title":"Infect Immun"},{"issue":"3","key":"11534_CR11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1046\/j.1365-2958.2002.03184.x","volume":"46","author":"GV Mukamolova","year":"2002","unstructured":"Mukamolova GV, Turapov OA, Young DI, Kaprelyants AS, Kell DB, Young M. A family of autocrine growth factors in Mycobacterium tuberculosis. Mol Microbiol. 2002;46(3):623\u201335.","journal-title":"Mol Microbiol"},{"issue":"3","key":"11534_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.tube.2010.04.001","volume":"90","author":"MA Flores Valdez","year":"2010","unstructured":"Flores Valdez MA, Schoolnik GK. DosR-regulon genes induction in Mycobacterium bovis BCG under aerobic conditions. Tuberculosis (Edinb). 2010;90(3):197\u2013200.","journal-title":"Tuberculosis (Edinb)"},{"issue":"1","key":"11534_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tube.2010.09.006","volume":"91","author":"A Kapopoulou","year":"2011","unstructured":"Kapopoulou A, Lew JM, Cole ST. The mycobrowser portal: a comprehensive and manually annotated resource for mycobacterial genomes. Tuberculosis (Edinb). 2011;91(1):8\u201313.","journal-title":"Tuberculosis (Edinb)"},{"issue":"8","key":"11534_CR14","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.micinf.2006.03.018","volume":"8","author":"EM Leyten","year":"2006","unstructured":"Leyten EM, Lin MY, Franken KL, Friggen AH, Prins C, van Meijgaarden KE, Voskuil MI, Weldingh K, Andersen P, Schoolnik GK, et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect. 2006;8(8):2052\u201360.","journal-title":"Microbes Infect"},{"issue":"5","key":"11534_CR15","doi-asserted-by":"publisher","first-page":"e5590","DOI":"10.1371\/journal.pone.0005590","volume":"4","author":"SD Schuck","year":"2009","unstructured":"Schuck SD, Mueller H, Kunitz F, Neher A, Hoffmann H, Franken KL, Repsilber D, Ottenhoff TH, Kaufmann SH, Jacobsen M. Identification of T-cell antigens specific for latent mycobacterium tuberculosis infection. PLoS One. 2009;4(5):e5590.","journal-title":"PLoS One"},{"issue":"8","key":"11534_CR16","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1128\/CVI.00111-09","volume":"16","author":"GF Black","year":"2009","unstructured":"Black GF, Thiel BA, Ota MO, Parida SK, Adegbola R, Boom WH, Dockrell HM, Franken KL, Friggen AH, Hill PC, et al. Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol. 2009;16(8):1203\u201312.","journal-title":"Clin Vaccine Immunol"},{"key":"11534_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2334-12-10","volume":"12","author":"NN Chegou","year":"2012","unstructured":"Chegou NN, Black GF, Loxton AG, Stanley K, Essone PN, Klein MR, Parida SK, Kaufmann SH, Doherty TM, Friggen AH, et al. Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting. BMC Infect Dis. 2012;12:10.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"11534_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.clim.2006.10.010","volume":"122","author":"SB Sable","year":"2007","unstructured":"Sable SB, Kalra M, Verma I, Khuller GK. Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity. Clin Immunol. 2007;122(3):239\u201351.","journal-title":"Clin Immunol"},{"key":"11534_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1755-8794-1-18","volume":"1","author":"A Zvi","year":"2008","unstructured":"Zvi A, Ariel N, Fulkerson J, Sadoff JC, Shafferman A. Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses. BMC Med Genomics. 2008;1:18.","journal-title":"BMC Med Genomics"},{"issue":"8","key":"11534_CR20","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1073\/pnas.88.8.3111","volume":"88","author":"MH Lee","year":"1991","unstructured":"Lee MH, Pascopella L, Jacobs WR Jr, Hatfull GF. Site-specific integration of mycobacteriophage L5: integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guerin. Proc Natl Acad Sci U S A. 1991;88(8):3111\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"11534_CR21","doi-asserted-by":"publisher","first-page":"9408","DOI":"10.1128\/JVI.00707-07","volume":"81","author":"EJ Im","year":"2007","unstructured":"Im EJ, Saubi N, Virgili G, Sander C, Teoh D, Gatell JM, McShane H, Joseph J, Hanke T. Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J Virol. 2007;81(17):9408\u201318.","journal-title":"J Virol"},{"key":"11534_CR22","first-page":"253","volume":"13","author":"E Broset","year":"2019","unstructured":"Broset E, Saubi N, Guitart N, Aguilo N, Uranga S, Kilpelainen A, Eto Y, Hanke T, Gonzalo-Asensio J, Martin C, et al. MTBVAC-based TB-HIV vaccine is safe, elicits HIV-T cell responses, and protects against Mycobacterium tuberculosis in mice. Mol Ther. 2019;13:253\u201364.","journal-title":"Mol Ther"},{"issue":"8","key":"11534_CR23","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1080\/21645515.2017.1316911","volume":"13","author":"A Mahant","year":"2017","unstructured":"Mahant A, Saubi N, Eto Y, Guitart N, Gatell JM, Hanke T, Joseph J. Preclinical development of BCG.HIVA(2auxo.int), harboring an integrative expression vector, for a HIV-TB pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity. Hum Vaccin Immunother. 2017;13(8):1798\u2013810.","journal-title":"Hum Vaccin Immunother"},{"key":"11534_CR24","first-page":"14017","volume":"1","author":"N Saubi","year":"2014","unstructured":"Saubi N, Gea-Mallorqui E, Ferrer P, Hurtado C, Sanchez-Ubeda S, Eto Y, Gatell JM, Hanke T, Joseph J. Engineering new mycobacterial vaccine design for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG. Mol Ther. 2014;1:14017.","journal-title":"Mol Ther"},{"issue":"16","key":"11534_CR25","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1128\/JB.181.16.4780-4789.1999","volume":"181","author":"MS Pavelka Jr","year":"1999","unstructured":"Pavelka MS Jr, Jacobs WR Jr. Comparison of the construction of unmarked deletion mutations in Mycobacterium smegmatis, Mycobacterium bovis bacillus Calmette-Guerin, and Mycobacterium tuberculosis H37Rv by allelic exchange. J Bacteriol. 1999;181(16):4780\u20139.","journal-title":"J Bacteriol"},{"issue":"2","key":"11534_CR26","first-page":"64","volume":"9","author":"M Ashayeri-Panah","year":"2017","unstructured":"Ashayeri-Panah M, Eftekhar F, Kazemi B, Joseph J. Cloning, optimization of induction conditions and purification of Mycobacterium tuberculosis Rv1733c protein expressed in Escherichia coli. Iran J Microbiol. 2017;9(2):64\u201373.","journal-title":"Iran J Microbiol"},{"issue":"7","key":"11534_CR27","doi-asserted-by":"publisher","first-page":"e0235563","DOI":"10.1371\/journal.pone.0235563","volume":"15","author":"Y Tsuji","year":"2020","unstructured":"Tsuji Y. Transmembrane protein western blotting: impact of sample preparation on detection of SLC11A2 (DMT1) and SLC40A1 (ferroportin). PLoS One. 2020;15(7):e0235563.","journal-title":"PLoS One"},{"key":"11534_CR28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fimmu.2014.00152","volume":"5","author":"AC da Costa","year":"2014","unstructured":"da Costa AC, Nogueira SV, Kipnis A, Junqueira-Kipnis AP. Recombinant BCG: innovations on an old vaccine. Scope of BCG strains and strategies to improve long-lasting memory. Front Immunol. 2014;5:152.","journal-title":"Front Immunol"},{"key":"11534_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3389\/fmicb.2014.00517","volume":"5","author":"MM Serra-Vidal","year":"2014","unstructured":"Serra-Vidal MM, Latorre I, Franken KL, Diaz J, de Souza-Galvao ML, Casas I, Maldonado J, Mila C, Solsona J, Jimenez-Fuentes MA, et al. Immunogenicity of 60 novel latency-related antigens of Mycobacterium tuberculosis. Front Microbiol. 2014;5:517.","journal-title":"Front Microbiol"},{"issue":"2","key":"11534_CR30","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1128\/IAI.01137-06","volume":"75","author":"V Roupie","year":"2007","unstructured":"Roupie V, Romano M, Zhang L, Korf H, Lin MY, Franken KL, Ottenhoff TH, Klein MR, Huygen K. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun. 2007;75(2):941\u20139.","journal-title":"Infect Immun"},{"issue":"11","key":"11534_CR31","doi-asserted-by":"publisher","first-page":"7948","DOI":"10.4049\/jimmunol.181.11.7948","volume":"181","author":"S Bertholet","year":"2008","unstructured":"Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N, Laughlin EM, Baldwin SL, Vedvick TS, Coler RN, et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol. 2008;181(11):7948\u201357.","journal-title":"J Immunol"},{"issue":"8","key":"11534_CR32","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1128\/IAI.71.8.4789-4794.2003","volume":"71","author":"VV Yeremeev","year":"2003","unstructured":"Yeremeev VV, Kondratieva TK, Rubakova EI, Petrovskaya SN, Kazarian KA, Telkov MV, Biketov SF, Kaprelyants AS, Apt AS. Proteins of the Rpf family: immune cell reactivity and vaccination efficacy against tuberculosis in mice. Infect Immun. 2003;71(8):4789\u201394.","journal-title":"Infect Immun"},{"issue":"8","key":"11534_CR33","doi-asserted-by":"publisher","first-page":"e71243","DOI":"10.1371\/journal.pone.0071243","volume":"8","author":"W Zhang","year":"2013","unstructured":"Zhang W, Zhang Y, Zheng H, Pan Y, Liu H, Du P, Wan L, Liu J, Zhu B, Zhao G, et al. Genome sequencing and analysis of BCG vaccine strains. PLoS One. 2013;8(8):e71243.","journal-title":"PLoS One"},{"issue":"1","key":"11534_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1128\/IAI.72.1.381-388.2004","volume":"72","author":"J Vekemans","year":"2004","unstructured":"Vekemans J, Ota MO, Sillah J, Fielding K, Alderson MR, Skeiky YA, Dalemans W, McAdam KP, Lienhardt C, Marchant A. Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test design. Infect Immun. 2004;72(1):381\u20138.","journal-title":"Infect Immun"},{"issue":"6","key":"11534_CR35","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1128\/IAI.01990-06","volume":"75","author":"A Geluk","year":"2007","unstructured":"Geluk A, Lin MY, van Meijgaarden KE, Leyten EM, Franken KL, Ottenhoff TH, Klein MR. T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination. Infect Immun. 2007;75(6):2914\u201321.","journal-title":"Infect Immun"},{"issue":"10","key":"11534_CR36","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1586\/erv.12.94","volume":"11","author":"N Dalmia","year":"2012","unstructured":"Dalmia N, Ramsay AJ. Prime-boost approaches to tuberculosis vaccine development. Expert Rev Vaccines. 2012;11(10):1221\u201333.","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"11534_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.0300-9475.2004.01471.x","volume":"60","author":"AW Olsen","year":"2004","unstructured":"Olsen AW, Brandt L, Agger EM, van Pinxteren LA, Andersen P. The influence of remaining live BCG organisms in vaccinated mice on the maintenance of immunity to tuberculosis. Scand J Immunol. 2004;60(3):273\u20137.","journal-title":"Scand J Immunol"},{"issue":"6","key":"11534_CR38","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.vaccine.2005.07.033","volume":"24","author":"JF Griffin","year":"2006","unstructured":"Griffin JF, Mackintosh CG, Rodgers CR. Factors influencing the protective efficacy of a BCG homologous prime-boost vaccination regime against tuberculosis. Vaccine. 2006;24(6):835\u201345.","journal-title":"Vaccine"},{"issue":"32","key":"11534_CR39","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1016\/j.vaccine.2010.05.063","volume":"28","author":"C Shi","year":"2010","unstructured":"Shi C, Chen L, Chen Z, Zhang Y, Zhou Z, Lu J, Fu R, Wang C, Fang Z, Fan X. Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein. Vaccine. 2010;28(32):5237\u201344.","journal-title":"Vaccine"},{"issue":"3","key":"11534_CR40","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1128\/CVI.00721-14","volume":"22","author":"K Bhatt","year":"2015","unstructured":"Bhatt K, Verma S, Ellner JJ, Salgame P. Quest for correlates of protection against tuberculosis. Clin Vaccine Immunol. 2015;22(3):258\u201366.","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"11534_CR41","doi-asserted-by":"publisher","first-page":"e1004603","DOI":"10.1371\/journal.ppat.1004603","volume":"11","author":"HP Gideon","year":"2015","unstructured":"Gideon HP, Phuah J, Myers AJ, Bryson BD, Rodgers MA, Coleman MT, Maiello P, Rutledge T, Marino S, Fortune SM, et al. Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization. PLoS Pathog. 2015;11(1):e1004603.","journal-title":"PLoS Pathog"},{"issue":"1","key":"11534_CR42","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4049\/jimmunol.1200061","volume":"190","author":"AM Green","year":"2013","unstructured":"Green AM, Difazio R, Flynn JL. IFN-gamma from CD4 T cells is essential for host survival and enhances CD8 T cell function during Mycobacterium tuberculosis infection. J Immunol. 2013;190(1):270\u20137.","journal-title":"J Immunol"},{"issue":"6","key":"11534_CR43","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1084\/jem.178.6.2249","volume":"178","author":"JL Flynn","year":"1993","unstructured":"Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med. 1993;178(6):2249\u201354.","journal-title":"J Exp Med"},{"issue":"15","key":"11534_CR44","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098\u2013104.","journal-title":"N Engl J Med"},{"issue":"2","key":"11534_CR45","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.tube.2009.01.001","volume":"89","author":"DM Higgins","year":"2009","unstructured":"Higgins DM, Sanchez-Campillo J, Rosas-Taraco AG, Lee EJ, Orme IM, Gonzalez-Juarrero M. Lack of IL-10 alters inflammatory and immune responses during pulmonary Mycobacterium tuberculosis infection. Tuberculosis (Edinb). 2009;89(2):149\u201357.","journal-title":"Tuberculosis (Edinb)"},{"issue":"12","key":"11534_CR46","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1128\/CVI.00289-07","volume":"14","author":"R Hussain","year":"2007","unstructured":"Hussain R, Talat N, Shahid F, Dawood G. Longitudinal tracking of cytokines after acute exposure to tuberculosis: association of distinct cytokine patterns with protection and disease development. Clin Vaccine Immunol. 2007;14(12):1578\u201386.","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"11534_CR47","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/path.4399","volume":"234","author":"L Heitmann","year":"2014","unstructured":"Heitmann L, Abad Dar M, Schreiber T, Erdmann H, Behrends J, McKenzie AN, Brombacher F, Ehlers S, Holscher C. The IL-13\/IL-4Ralpha axis is involved in tuberculosis-associated pathology. J Pathol. 2014;234(3):338\u201350.","journal-title":"J Pathol"},{"issue":"12","key":"11534_CR48","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/j.1348-0421.2000.tb02592.x","volume":"44","author":"I Sugawara","year":"2000","unstructured":"Sugawara I, Yamada H, Mizuno S, Iwakura Y. IL-4 is required for defense against mycobacterial infection. Microbiol Immunol. 2000;44(12):971\u20139.","journal-title":"Microbiol Immunol"},{"issue":"4","key":"11534_CR49","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1128\/IAI.69.4.2666-2674.2001","volume":"69","author":"AA Chackerian","year":"2001","unstructured":"Chackerian AA, Perera TV, Behar SM. Gamma interferon-producing CD4+ T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis. Infect Immun. 2001;69(4):2666\u201374.","journal-title":"Infect Immun"},{"issue":"2","key":"11534_CR50","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4049\/jimmunol.1601340","volume":"199","author":"L Moreira-Teixeira","year":"2017","unstructured":"Moreira-Teixeira L, Redford PS, Stavropoulos E, Ghilardi N, Maynard CL, Weaver CT, Freitas do Rosario AP, Wu X, Langhorne J, O\u2019Garra A. T cell-derived IL-10 impairs host resistance to Mycobacterium tuberculosis infection. J Immunol. 2017;199(2):613\u201323.","journal-title":"J Immunol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11534-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:03:20Z","timestamp":1761221000000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11534-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11534"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11534-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal husbandry and experimental procedures were conducted in accordance with established Institutional Animal Care and Use Committee (IACUC)-approved protocols at Shahid Beheshti University and were approved by the Research and Ethics Committee of Shahid Beheshti University, Tehran, Iran (Approval number D\/920\/2289). All methods are reported in accordance with ARRIVE guidelines for the reporting of animal experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1338"}}